GlassScriptPhysician profile
Patrick T Ottuso
NPI 1386627867
$4,082.65
in general payments reported to CMS, 2019-2025
28 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $462 · 2021: $600 · 2022: $766 · 2023: $557 · 2024: $864 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.63 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $718.43 | 2019-2024 | |
| Lilly USA, LLC | $517.51 | 2019-2024 | Olumiant |
| Janssen Biotech, INC. | $421.47 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $300.68 | 2019-2024 | |
| Leo Pharma INC. | $281.68 | 2019-2024 | Adbry |
| Incyte Corporation | $228.60 | 2022-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $189.84 | 2023-2024 | Dupixent |
| Almirall LLC | $153.73 | 2021-2024 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.48 | 2019-2021 | |
| Dermavant Sciences, INC. | $141.04 | 2023 | Vtama |
| Biofrontera INC. | $122.08 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $107.80 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $98.63 | 2019-2024 | Aklief, Dysport |
| Vyne Pharmaceuticals INC. | $92.14 | 2020-2021 | |
| Pfizer INC. | $88.76 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.35 | 2021-2022 | |
| Boston Scientific Corporation | $64.38 | 2025 | Watchman Flx |
| Genzyme Corporation | $58.42 | 2022-2023 | |
| Ucb, INC. | $38.49 | 2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $36.04 | 2021 | |
| Paratek Pharmaceuticals, INC. | $35.75 | 2023 | Nuzyra |
| Dermira, INC. | $29.48 | 2020 | |
| Mission Pharmacal Company | $27.04 | 2021 | |
| Amgen INC. | $25.31 | 2022 | |
| Verrica Pharmaceuticals INC. | $24.78 | 2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $23.42 | 2023 | Sotyktu |
| Merz North America, INC. | $20.29 | 2021 | |
| Medtronic, INC. | $15.03 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ottuso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.